Praxis Precision Medicines Inc

NASDAQ:PRAX  
40.47
+3.31 (+8.91%)
Products, Regulatory, Other Pre-Announcement

Praxis Precision Medicines Provides Update On PRAX-114 IND Submission For The Treatment Of Major Depressive Disorder

Published: 11/17/2020 12:54 GMT
(PRAX) - Praxis Precision Medicines Provides Update on Prax-114 Ind Submission for the Treatment of Major Depressive Disorder.
Praxis Precision Medicines Inc - Expects to Initiate Phase 2/3 Clinical Trial for Prax-114 in Mdd in 1h21.
Praxis Precision Medicines - Has Got Comments From FDA on Full Clinical Hold of Its Ind Submission for Prax-114 for Treatment of Mdd.
Praxis Precision Medicines - is in Dialogue With FDA and Intends to Explore Potential Options to Accelerate Initiation of Phase 2/3 Clinical Trial.
Praxis Precision - Believes Results of Ongoing Standard Fertility, Reproductive Studies With Available Toxicology Package Will Satisfy FDA Request.
Praxis Precision Medicines - FDA Also Requested Updates to Investigator's Brochure and to Requirements for Contraception in Protocol.